Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lisata Therapeutics, Inc. - Common Stock (NQ:LSTA)

2.965 -0.265 (-8.20%)
Streaming Delayed Price Updated: 11:55 AM EDT, Apr 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 56,846
Open 3.250
Bid (Size) 2.910 (1,100)
Ask (Size) 3.020 (300)
Prev. Close 3.230
Today's Range 2.840 - 3.270
52wk Range 1.810 - 5.070
Shares Outstanding 60,533,064
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Halper Sadeh LLC is Investigating Whether TALK, UBFO, LSTA are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
From Lisata Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+51.3%
+51.3%
1 Month
-40.8%
-40.8%
3 Month
+37.3%
+37.3%
6 Month
+21.0%
+21.0%
1 Year
+30.0%
+30.0%

More News

Read More
News headline image
Halper Sadeh LLC Reminds Shareholders of SKYT, NATH, SNCY, LSTA of the Firm’s Investigations
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SkyWater Technology, Inc. (Nasdaq - SKYT), Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC Encourages NATH, PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC Encourages SKYT, NATH, LSTA Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via GlobeNewswire
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
News headline image
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
From Lisata Therapeutics, Inc.
Via GlobeNewswire
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
News headline image
LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Lisata Shares Nearly Double On Buyout Offer: Here Are The Details ↗
Via Stocktwits
Topics Workforce
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (Nasdaq - SNCY), Ventyx Biosciences, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
News headline image
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics (NASDAQ:LSTA) Reports Narrower-Than-Expected Q3 2025 Loss ↗
Via Chartmill
News headline image
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Lisata Therapeutics, Inc. - Common Stock publicly traded?
Yes, Lisata Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Lisata Therapeutics, Inc. - Common Stock trade on?
Lisata Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lisata Therapeutics, Inc. - Common Stock?
The ticker symbol for Lisata Therapeutics, Inc. - Common Stock is LSTA on the Nasdaq Stock Market
What is the current price of Lisata Therapeutics, Inc. - Common Stock?
The current price of Lisata Therapeutics, Inc. - Common Stock is 2.965
When was Lisata Therapeutics, Inc. - Common Stock last traded?
The last trade of Lisata Therapeutics, Inc. - Common Stock was at 04/20/26 11:55 AM ET
What is the market capitalization of Lisata Therapeutics, Inc. - Common Stock?
The market capitalization of Lisata Therapeutics, Inc. - Common Stock is 179.48M
How many shares of Lisata Therapeutics, Inc. - Common Stock are outstanding?
Lisata Therapeutics, Inc. - Common Stock has 179M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.